[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fP2eKxF_2AxJRjxzZrWDTvcM_37ZrPgjmcCFscytbzpg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"University of Haifa",[4],96,false,21,0,18409,2,94,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Stroke",7,{"name":18,"count":19},"Parkinson Disease",5,{"name":21,"count":22},"Major Depressive Disorder",4,{"name":24,"count":22},"Pelvic Floor Muscle Weakness",{"name":26,"count":27},"Stress Disorders, Post-Traumatic",3,{"name":29,"count":27},"Stress Related Disorder",{"name":31,"count":27},"Mental Health Issue",{"name":33,"count":27},"Low Back Pain",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05133804","Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD","2025-07-01","Methylphenidate",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,73,91],{"intervention":39,"totalTrials":49,"cells":50},1,{"EARLY_PHASE1":51,"PHASE1":53,"PHASE2":55,"PHASE3":67,"PHASE4":69,"NA":71},{"trials":52,"activeCount":9},[],{"trials":54,"activeCount":9},[],{"trials":56,"activeCount":49,"soonestReadout":38},[57],{"nctId":36,"briefTitle":37,"status":58,"phases":59,"primaryCompletion":38,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"RECRUITING",[43],"2025-12-01","2022-06-01",53,[64],"Posttraumatic Stress Disorder",[39,66],"Reboxetine",{"trials":68,"activeCount":9},[],{"trials":70,"activeCount":9},[],{"trials":72,"activeCount":9},[],{"intervention":66,"totalTrials":49,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":85,"PHASE4":87,"NA":89},{"trials":76,"activeCount":9},[],{"trials":78,"activeCount":9},[],{"trials":80,"activeCount":49,"soonestReadout":38},[81],{"nctId":36,"briefTitle":37,"status":58,"phases":82,"primaryCompletion":38,"completion":60,"start":61,"enrollment":62,"conditions":83,"interventions":84},[43],[64],[39,66],{"trials":86,"activeCount":9},[],{"trials":88,"activeCount":9},[],{"trials":90,"activeCount":9},[],{"intervention":92,"totalTrials":49,"cells":93},"Ibuprofen 400 mg",{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":104},{"trials":95,"activeCount":9},[],{"trials":97,"activeCount":9},[],{"trials":99,"activeCount":9},[],{"trials":101,"activeCount":9},[],{"trials":103,"activeCount":9},[],{"trials":105,"activeCount":9},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":117},"NCT03952715","Can Training Increase Reporting Accuracy and Study Power in Human Pain Trials","UNKNOWN",[46],"2019-07","2018-04-17",100,[115,116],"Healthy","Placebo Response",[92]]